Immorna, a Chinese developer of mRNA-based therapeutics, has snapped up $100 million in Series A+ and A++ rounds in a bid to support the clinical development of its drug candidates, according to an announcement on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
